Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people

Background:  To investigate whether the pharmacodynamics and pharmacokinetics of omeprazole (OPZ) are dependent of the CYP2C19 genotype status in Chinese people.

[1]  P. Lundborg,et al.  Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole , 1990, Clinical pharmacology and therapeutics.

[2]  M O Karlsson,et al.  A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog. , 2000, The Journal of pharmacology and experimental therapeutics.

[3]  S. Higuchi,et al.  Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects. , 1996, Clinical pharmacology and therapeutics.

[4]  M. Onda,et al.  Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations , 2001, Journal of Gastroenterology.

[5]  K. Safranow,et al.  Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection , 2005, European Journal of Clinical Pharmacology.

[6]  Na Gao,et al.  Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype , 2006, European Journal of Clinical Pharmacology.

[7]  H. Zhou,et al.  Individual and ethnic differences in CYP2C19 activity in Chinese populations. , 2000, Acta pharmacologica Sinica.

[8]  G. Sachs,et al.  Pharmacological aspects of acid secretion , 1995, Digestive Diseases and Sciences.

[9]  L. Bertilsson,et al.  Omeprazole treatment of Korean patients: effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes. , 2004, Basic & clinical pharmacology & toxicology.

[10]  S. Higuchi,et al.  Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects , 1996 .

[11]  G R Wilkinson,et al.  Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. , 1994, Molecular pharmacology.

[12]  K. Ohashi,et al.  Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH , 2001, Alimentary pharmacology & therapeutics.

[13]  T Ishizaki,et al.  CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. , 1998, Clinical pharmacology and therapeutics.

[14]  M. Kasuga,et al.  CYP2C19 Genotype and Pharmacokinetics of Three Proton Pump Inhibitors in Healthy Subjects , 2001, Pharmaceutical Research.

[15]  Leif Bertilsson,et al.  A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants , 2006, Clinical pharmacology and therapeutics.

[16]  A. Chow,et al.  Omeprazole as a CYP2C19 Marker in Chinese Subjects: Assessment of Its Gene‐Dose Effect and Intrasubject Variability , 2004, Journal of clinical pharmacology.

[17]  G R Wilkinson,et al.  The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.

[18]  H. Mieno,et al.  Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H2‐receptor antagonist , 2003, Alimentary pharmacology & therapeutics.

[19]  J. Miners,et al.  Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. , 1994, British journal of clinical pharmacology.

[20]  L. Bertilsson,et al.  Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S‐mephenytoin , 1992, Clinical pharmacology and therapeutics.

[21]  T. Starzynska,et al.  Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients , 2006, European Journal of Clinical Pharmacology.

[22]  T. Andersson,et al.  Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. , 1990, British journal of clinical pharmacology.

[23]  U. Haglund,et al.  Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man. , 1983, Gut.

[24]  L. Bertilsson,et al.  Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism. , 2000, Gastroenterology.

[25]  M. Fromm,et al.  Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein , 2001, Naunyn-Schmiedeberg's Archives of Pharmacology.

[26]  G. Sachs.  Physiology of the Parietal Cell and Therapeutic Implications , 2003, Pharmacotherapy.

[27]  L. Bertilsson,et al.  Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19. , 1995, British journal of clinical pharmacology.

[28]  O. Junghard,et al.  The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH , 2002, European Journal of Clinical Pharmacology.

[29]  J. Goldstein,et al.  Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. , 1997, The Journal of pharmacology and experimental therapeutics.

[30]  L. Bertilsson,et al.  Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. , 1990, Therapeutic drug monitoring.

[31]  Yuan Zhang,et al.  Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. , 1992, Pharmacogenetics.

[32]  D. Flockhart,et al.  Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.